BCL2 and cancer: These often regulate important cellular processes, like proliferation, metabolic or cell death regulation179, and the BCL2 protein family is often differentially regulated in response to BET inhibitor treatment in several cancer types.180–182 As with “methylation-related” enzyme inhibitors, BETi are in ongoing clinical trials as single agents, but more often as combination therapy.